Author

R. M. Barfield

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 2 Organism:rat· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

D. Rabuka· 3 shared A. O. Ogunkoya· 2 shared C. Hickle· 2 shared D. Yeo· 2 shared F. Zhang· 2 shared M. Bauzon· 2 shared P. M. Drake· 2 shared S. Chuprakov· 2 shared

Activity by Year

2019-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersPharmacology & Toxicology

D. Rabuka

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Tandem-Cleavage Linkers Improve the In Vivo Stability and Tolerability of Antibody-Drug Conjugates

S. Chuprakov, A. O. Ogunkoya, R. M. Barfield, M. Bauzon, C. Hickle, Y. C. Kim, D. Yeo, F. Zhang, D. Rabuka, P. M. Drake

This paper develops tandem-cleavage linkers to improve ADC stability and tolerability, showing better hematopoietic safety in rat studies.

bioRxiv · Jan 19, 2021Pharmacology & Toxicology

A novel HER2-targeted antibody-drug conjugate offers the possibility of clinical dosing at trastuzumab-equivalent exposure levels

R. M. Barfield, Y. C. Kim, S. Chuprakov, F. Zhang, M. Bauzon, A. O. Ogunkoya, D. Yeo, C. Hickle, M. D. Pegram, D. Rabuka, P. M. Drake

This paper develops a novel HER2-targeted ADC, CAT-01-106, showing improved efficacy and tolerability compared to T-DM1 at equivalent payload dosing.

bioRxiv · Mar 13, 2020Pharmacology & Toxicology

Systematic identification of regulators of antibody-drug conjugate toxicity using CRISPR-Cas9 screens

C. K. Tsui, R. M. Barfield, C. R. Fischer, D. W. Morgens, A. Li, B. A. H. Smith, C. R. Bertozzi, D. Rabuka, M. C. Bassik

This study uses CRISPR-Cas9 screens to identify genes regulating antibody-drug conjugate (ADC) toxicity, revealing endolysosomal trafficking regulators and mechanisms of ADC resistance.

bioRxiv · Mar 3, 2019 · PreprintCancer Biology